Targeted drug delivery based on gold nanoparticle derivatives

Current Pharmaceutical Design

Volumn 23, Issue 20, 2017, Pages 2918-2929

  Gholipourmalekabadi, Mazaher ^a,b   Mobaraki, Mohammadmahdi ^c   Ghaffari, Maryam ^c   Zarebkohan, Amir ^d   Omrani, Vahid Fallah ^b   Urbanska, Aleksandra M ^e   Seifalian, Alexander ^f  

^a IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c AMIRKABIR UNIVERSITY OF TECHNOLOGY   (Iran)

^d TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e Och Spine at New York Presbyterian Hospitals   (United States)

^f ROYAL VETERINARY COLLEGE   (United Kingdom)

Author keywords

Drug delivery; Gold nanoparticle; Nanoparticles; Nanotechnology; Surface modification; Targeted delivery

Indexed keywords

ALBUMIN; AVENIN; CARBOHYDRATE; DEXAMETHASONE; GELATIN; GLIADIN; GOLD NANOPARTICLE; KANAMYCIN; MICRORNA; NANOPARTICLE; NANOSHELL; PACLITAXEL; SMALL INTERFERING RNA; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; ZEIN; DRUG; GOLD; METAL NANOPARTICLE;

ANTIBACTERIAL ACTIVITY; BIOCOMPATIBILITY; CELL MEMBRANE PERMEABILITY; CHEMICAL MODIFICATION; CYTOTOXICITY; DRUG COATING; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG TARGETING; HYDROPHOBICITY; NANOTECHNOLOGY; NONVIRAL GENE DELIVERY SYSTEM; PARTICLE SIZE; PHOTOTHERAPY; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; SURFACE PROPERTY; SYNTHESIS; TISSUE ENGINEERING; CHEMISTRY; HUMAN;

DRUG DELIVERY SYSTEMS; GOLD; HUMANS; METAL NANOPARTICLES; PHARMACEUTICAL PREPARATIONS;

EID: 85029647615     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612823666170419105413     Document Type: Review

References (137)

1. Park K. Controlled drug delivery systems: past forward and future back. J Controlled Release 2014; 190: 3-8.
2. Ranade VV, Cannon JB. Drug delivery systems. CRC press 2011.
3. Han G, Ghosh P, De M, Rotello VM. Drug and gene delivery using gold nanoparticles. Nanobiotechnology 2007; 3: 40-45.
4. Han G, Ghosh P, Rotello VM. Functionalized gold nanoparticles for drug delivery. Future Med 2007; 2: 113-23.
5. Grace AN, Pandian K. Antibacterial efficacy of aminoglycosidic antibiotics protected gold nanoparticles—A brief study. Colloids Surf Physicochem Eng Aspects 2007; 297: 63-70.
6. Graham T. Liquid diffusion applied to analysis. Philos Trans R Soc London 1861; 151: 183-224.
7. Kean W, Kean I. Clinical pharmacology of gold. Inflammopharmacology 2008; 16: 112-25.
8. Mody VV, Siwale R, Singh A, Mody HR. Introduction to metallic nanoparticles. J Pharm Bioallied Sci 2010; 2: 282.
9. Paciotti GF, Myer L, Weinreich D, et al. Colloidal gold: a novel nanoparticle vector for tumor directed drug delivery. Drug Deliv 2004; 11: 169-83.
10. Dykman L, Khlebtsov N. Gold nanoparticles in biomedical applications: recent advances and perspectives. Chem Soc Rev 2012; 41: 2256-82.
11. Ghosh P, Han G, De M, Kim CK, Rotello VM. Gold nanoparticles in delivery applications. Adv Drug Del Rev 2008; 60: 1307-15.
12. Urbanska AM, Karagiannis ED, Au AS, Dai SY, Mozafari M, Prakash S. What's next for gastrointestinal disorders: No needles? J Control Release 2016; 221: 48-61.
13. Araújo F, Shrestha N, Granja PL, Hirvonen J, Santos HA, Sarmento B. Safety and toxicity concerns of orally delivered nanoparticles as drug carriers. Expert Opin Drug Metab Toxicol 2015; 11: 381-93.
14. Florence AT. Nanoparticle uptake by the oral route: fulfilling its potential? Drug Discov Today: Technol 2005; 2: 75-81.
15. Hagens WI, Oomen AG, de Jong WH, Cassee FR, Sips AJ. What do we (need to) know about the kinetic properties of nanoparticles in the body? Regul Toxicol Pharmacol 2007; 49: 217-29.
16. Begley DJ. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol Ther 2004; 104: 29-45.
17. Bramini M, Ye D, Hallerbach A, et al. Imaging approach to mechanistic study of nanoparticle interactions with the blood-brain barrier. ACS Nano 2014; 8: 4304-12.
18. Alyautdin R, Khalin I, Nafeeza MI, Haron MH, Kuznetsov D. Nanoscale drug delivery systems and the blood-brain barrier. Int J Nanomed 2014; 9: 795-811.
19. Wohlfart S, Gelperina S, Kreuter J. Transport of drugs across the blood-brain barrier by nanoparticles. J Control Release 2012; 161: 264-73.
20. Gabathuler R. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol Dis 2010; 37: 48-57.
21. Alkilany AM, Murphy CJ. Toxicity and cellular uptake of gold nanoparticles: what we have learned so far? J Nanopart Res 2010; 12: 2313-33.
22. Cartiera MS, Johnson KM, Rajendran V, Caplan MJ, Saltzman WM. The uptake and intracellular fate of PLGA nanoparticles in epithelial cells. Biomaterials 2009; 30: 2790-8.
23. Xue X, Liang X-J. Overcoming drug efflux-based multidrug resistance in cancer with nanotechnology. Chin J Cancer 2012; 31: 100.
24. Christena LR, Mangalagowri V, Pradheeba P, et al. Copper nanoparticles as an efflux pump inhibitor to tackle drug resistant bacteria. RSC Adv 2015; 5: 12899-909.
25. Hostetler MJ, Wingate JE, Zhong CJ, et al. Alkanethiolate gold cluster molecules with core diameters from 1.5 to 5.2 nm: core and monolayer properties as a function of core size. Langmuir 1998; 14: 17-30.
26. Kumar V, Prud'Homme RK. Thermodynamic limits on drug loading in nanoparticle cores. J Pharm Sci 2008; 97: 4904-14.
27. Fischer KE, Jayagopal A, Nagaraj G, et al. Nanoengineered surfaces enhance drug loading and adhesion. Nano Lett 2011; 11: 1076-81.
28. Fischer KE, Nagaraj G, Daniels RH, et al. Hierarchical nanoengineered surfaces for enhanced cytoadhesion and drug delivery. Biomaterials 2011; 32: 3499-506.
29. Hu C-MJ, Aryal S, Zhang L. Nanoparticle-assisted combination therapies for effective cancer treatment. Ther Deliv 2010; 1: 323-34.
30. Meng H, Wang M, Liu H, et al. Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice. ACS Nano 2015; 9: 3540-57.
31. Sun R, Liu Y, Li SY, et al. Co-delivery of all-trans-retinoic acid and doxorubicin for cancer therapy with synergistic inhibition of cancer stem cells. Biomaterials 2015; 37: 405-14.
32. Kim D, Jeong YY, Jon S. A drug-loaded aptamer-gold nanoparticle bioconjugate for combined CT imaging and therapy of prostate cancer. ACS Nano 2010; 4: 3689-96.
33. Dong H, Du SR, Zheng XY, et al. Lanthanide nanoparticles: from design toward bioimaging and therapy. Chem Rev 2015; 115: 10725-815.
34. Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Del Rev 2014; 66: 2-25.
35. Kanamala M, Wilson WR, Yang M, Palmer BD, Wu Z. Mechanisms and biomaterials in pH-responsive tumour targeted drug delivery: A review. Biomaterials 2016; 85: 152-67.
36. Bamrungsap S, Zhao Z, Chen T, et al. Nanotechnology in therapeutics: a focus on nanoparticles as a drug delivery system. Nanomedicine 2012; 7: 1253-71.
37. Shargh VH, Hondermarck H, Liang M. Antibody-targeted biodegradable nanoparticles for cancer therapy. Nanomedicine 2016; 11: 63-79.
38. Torchilin VP, Lukyanov AN. Peptide and protein drug delivery to and into tumors: challenges and solutions. Drug Discov Today 2016; 8: 259-66.
39. Liu J, Wei T, Zhao J, et al. Multifunctional aptamer-based nanoparticles for targeted drug delivery to circumvent cancer resistance. Biomaterials 2016; 91: 44-56.
40. Sonavane G, Tomoda K, Makino K. Biodistribution of colloidal gold nanoparticles after intravenous administration: effect of particle size. Colloids Surf B Biointerfaces 2008; 66: 274-80.
41. Hamblin MR, Avci P. Applications of Nanoscience in Photomedicine. Elsevier 2015; 220.
42. Vigderman L, Zubarev ER. Therapeutic platforms based on gold nanoparticles and their covalent conjugates with drug molecules. Adv Drug Del Rev 2013; 65: 663-76.
43. Duncan B, Kim C, Rotello VM. Gold nanoparticle platforms as drug and biomacromolecule delivery systems. J Control Release 2010; 148: 122-7.
44. Heo DN, Ko W-K, Lee HR, et al. Titanium dental implants surface-immobilized with gold nanoparticles as osteoinductive agents for rapid osseointegration. J Colloid Interface Sci 2016; 469: 129-37.
45. Chen M, Yamamuro S, Farrell D, Majetich SA. Gold-coated iron nanoparticles for biomedical applications. J Appl Phys 2003; 93: 7551-3.
46. Mikalauskaite A, Kondrotas R, Niaura G, Jagminas A. Gold-coated cobalt ferrite nanoparticles via methionine-induced reduction. J Phys Chem C 2015; 119: 17398-407.
47. Kah J, Yeo E, He S, Engudar G. Gold nanorods in photomedicine. Appl Nanosci Photomed 2015: 221.
48. Mieszawska AJ, Mulder WJ, Fayad ZA, Cormode DP. Multifunctional gold nanoparticles for diagnosis and therapy of disease. Mol Pharm 2013; 10: 831-47.
49. Zhang Y, Shareena Dasari TP, Deng H, Yu H. Antimicrobial activity of gold nanoparticles and ionic gold. J Environ Sci Heal C 2015; 33: 286-327.
50. McKeon-Fischer K, Freeman J. Characterization of electrospun poly (L-lactide) and gold nanoparticle composite scaffolds for skeletal muscle tissue engineering. J Tissue Eng Regen Med 2011; 5: 560-8.
51. Fleischer S, Shevach M, Feiner R, Dvir T. Coiled fiber scaffolds embedded with gold nanoparticles improve the performance of engineered cardiac tissues. Nanoscale 2014; 6: 9410-4.
52. Akturk O, Kismet K, Yasti AC, et al. Wet electrospun silk fibroin/ gold nanoparticle 3D matrices for wound healing applications. RSC Adv 2016; 6: 13234-50.
53. Aktürk Ö, Keskin D. Collagen/PEO/gold nanofibrous matrices for skin tissue engineering. Turk J Biol 2016; 40: 380-98.
54. Fischer RL, McCoy MG, Grant SA. Electrospinning collagen and hyaluronic acid nanofiber meshes. J Tissue Eng Regen Med 2012; 23: 1645-54.
55. Wu L, Zhang J, Watanabe W. Physical and chemical stability of drug nanoparticles. Adv Drug Del Rev 2011; 63: 456-69.
56. Ernsting MJ, Murakami M, Roy A, Li S-D. Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. J Control Release 2013; 172: 782-94.
57. Sa LTM, de Souza Albernaz M, de Carvalho Patricio BF, et al. Biodistribution of nanoparticles: initial considerations. J Pharm Biomed Anal 2012; 70: 602-4.
58. Alric C, Miladi I, Kryza D, et al. The biodistribution of gold nanoparticles designed for renal clearance. Nanoscale 2013; 5: 5930-9.
59. Alkilany AM, Thompson LB, Boulos SP, Sisco PN, Murphy CJ. Gold nanorods: their potential for photothermal therapeutics and drug delivery, tempered by the complexity of their biological interactions. Adv Drug Del Rev 2012; 64: 190-9.
60. Xia Y, Li W, Cobley CM, et al. Gold nanocages: from synthesis to theranostic applications. Acc Chem Res 2011; 44: 914-24.
61. Chen J, Wiley BJ, Li Z, et al. Gold nanocages: engineering their structure for biomedical applications. Adv Mater 2005; 17: 2255-61.
62. Sironi L, Borzenkov M, Collini M, D’Alfonso L, Bouzin M, Chirico G. Interactions of Gold Nanostars with Cells. In: ed.^eds., Gold Nanostars. Springer 2015; pp. 61-74.
63. Perrault SD, Chan WC. Synthesis and surface modification of highly monodispersed, spherical gold nanoparticles of 50-200 nm. J Am Chem Soc 2010; 132: 11824.
64. Nativo P, Prior IA, Brust M. Uptake and intracellular fate of surface-modified gold nanoparticles. ACS nano 2008; 2: 1639-44.
65. Pissuwan D, Niidome T, Cortie MB. The forthcoming applications of gold nanoparticles in drug and gene delivery systems. J Control Release 2011; 149: 65-71.
66. Cobley CM, Au L, Chen J, Xia Y. Targeting gold nanocages to cancer cells for photothermal destruction and drug delivery. Expert Opin Drug Deliv 2010; 7: 577-87.
67. Fernandes R, Smyth NR, Muskens OL, et al. Interactions of skin with gold nanoparticles of different surface charge, shape, and functionality. Small 2015; 11: 713-21.
68. Valcárcel M, López-Lorente ÁI. Gold nanoparticles in analytical chemistry. Elsevier. 1st Edition 2014; 66: 642.
69. Grzelczak M, Pérez-Juste J, Mulvaney P, Liz-Marzán LM. Shape control in gold nanoparticle synthesis. Chem Soc Rev 2008; 37: 1783-91.
70. Jana NR, Gearheart L, Murphy CJ. Wet chemical synthesis of high aspect ratio cylindrical gold nanorods. J Physical Chem 2001; 105: 4065-7.
71. Samal AK, Sreeprasad TS, Pradeep T. Investigation of the role of NaBH4 in the chemical synthesis of gold nanorods. J Nanopart Res 2010; 12: 1777-86.
72. Zhao P, Li N, Astruc D. State of the art in gold nanoparticle synthesis. Coord Chem Rev 2013; 257: 638-65.
73. Shah KB. Non-directional conjugation of fluorescent antibodies to gold nanoparticles for stem cell therapy. In: ed. University of Arkansas, Fayetteville 2016; pp. 40.
74. Jazayeri MH, Amani H, Pourfatollah AA, Pazoki-Toroudi H, Sedighimoghaddam B. Various methods of gold nanoparticles (GNPs) conjugation to antibodies. Sen Biosensing Res 2016; 9: 17-22.
75. Moghimi SM, Hunter AC, Murray JC. Nanomedicine: current status and future prospects. FASEB J 2005; 19: 311-30.
76. Love JC, Estroff LA, Kriebel JK, Nuzzo RG, Whitesides GM. Selfassembled monolayers of thiolates on metals as a form of nanotechnology. Chem Rev 2005; 105: 1103-69.
77. Takae S, Akiyama Y, Otsuka H, Nakamura T, Nagasaki Y, Kataoka K. Ligand density effect on biorecognition by PEGylated gold nanoparticles: regulated interaction of RCA120 lectin with lactose installed to the distal end of tethered PEG strands on gold surface. Biomacromolecules 2005; 6: 818-24.
78. Khalil H, Mahajan D, Rafailovich M, Gelfer M, Pandya K. Synthesis of zerovalent nanophase metal particles stabilized with poly(ethylene glycol). Langmuir 2004; 20: 6896-903.
79. Otsuka H, Akiyama Y, Nagasaki Y, Kataoka K. Quantitative and reversible lectin-induced association of gold nanoparticles modified with alpha-lactosyl-omega-mercapto-poly(ethylene glycol). J Am Chem Soc 2001; 123: 8226-30.
80. Olivier JC, Huertas R, Lee HJ, Calon F, Pardridge WM. Synthesis of pegylated immunonanoparticles. Pharm Res 2002; 19: 1137-43.
81. Otsuka H, Nagasaki Y, Kataoka K. PEGylated nanoparticles for biological and pharmaceutical applications. Adv Drug Deliv Rev 2003; 55: 403-19.
82. Shimmin RG, Schoch AB, Braun PV. Polymer size and concentration effects on the size of gold nanoparticles capped by polymeric thiols. Langmuir 2004; 20: 5613-20.
83. Bergen JM, Von Recum HA, Goodman TT, Massey AP, Pun SH. Gold nanoparticles as a versatile platform for optimizing physicochemical parameters for targeted drug delivery. Macromol Biosci 2006; 6: 506-16.
84. Maltzahn J-V, Park J-H, Agrawal A, Bandaru N-K, Sailor M-J, Bhatia S-N. Computationally guided photothermal tumor therapy using long-circulating gold nanorod antennas. Cancer Res 2009; 69: 3892-900.
85. Pham T, Jackson J-B, Halas NJ, Lee T-R. Preparation and characterization of gold nanoshells coated with self-Assembled monolayers. Langmuir 2002; 18: 4915-20.
86. Park H, Yang J, Seo S, et al. Multifunctional nanoparticles for photothermally controlled drug delivery and magnetic resonance imaging enhancement. Small, 2008; 4: 192-6.
87. Khanadeev V, Khlebtsov B, Khlebtsov N. Optical properties of monodisperse gold nanoshells on silica cores. In: ed.^eds., Saratov Fall Meeting 2015. Int Soc Optic Photonics 2016; pp. 991719-991719-6.
88. Iqbal M, Usanase G, Oulmi K, et al. Preparation of gold nanoparticles and determination of their particles size via different methods. Mater Res Bull 2016; 79: 97-104.
89. Ballarin B, Barreca D, Cassani MC, et al. Gold nanoparticlesdecorated fluoroalkylsilane nano-assemblies for electrocatalytic applications. Appl Surf Sci 2016; 362: 42-8.
90. Alex S, Tiwari A. Functionalized gold nanoparticles: synthesis, properties and applications—a review. Journal of nanoscience and nanotechnology 2015; 15: 1869-94.
91. Naldini L. Gene therapy returns to centre stage. Nature 2015; 526: 351-60.
92. Roy K, Mao HQ, Huang SK, Leong KW. Oral gene delivery with chitosan--DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med 1999; 5: 387-91.
93. Luo D, Saltzman WM. Synthetic DNA delivery systems. Nat Biotechnol 2000; 18: 33-7.
94. Yeh P, Perricaudet M. Advances in adenoviral vectors: from genetic engineering to their biology. FASEB J 1997; 11: 615-23.
95. Check E. A tragic setback. Nature 2002; 420: 116-8.
96. Sershen SR, Westcott SL, Halas NJ, West JL. Temperaturesensitive polymer-nanoshell composites for photothermally modulated drug delivery. J Biomed Mater Res 2000; 51: 293-8.
97. Zhang S, Zhao B, Jiang H, Wang B, Ma B. Cationic lipids and polymers mediated vectors for delivery of siRNA. J Control Release 2007; 123: 1-10.
98. Gupta P, Vermani K, Garg S. Hydrogels: from controlled release to pH-responsive drug delivery. Drug Discov Today 2002; 7: 569-79.
99. Vasir JK, Reddy MK, Labhasetwar VD. Nanosystems in drug targeting: opportunities and challenges. Curr Nanosci 2005; 1: 47-64.
100. Pissuwan D, Valenzuela SM, Killingsworth MC, Xu X, Cortie MB. Targeted destruction of murine macrophage cells with bioconjugated gold nanorods. J Nanopart Res 2007; 9: 1109-24.
101. Felnerova D, Viret JF, Gluck R, Moser C. Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs. Curr Opin Biotechnol 2004; 15: 518-29.
102. Pissuwan D, Niidome T, Cortie MB. The forthcoming applications of gold nanoparticles in drug and gene delivery systems. J Control Release 2011; 149: 65-71.
103. Bonoiu AC, Mahajan SD, Ding H, et al. Nanotechnology approach for drug addiction therapy: gene silencing using delivery of gold nanorod-siRNA nanoplex in dopaminergic neurons. Proc Natl Acad Sci U S A 2009; 106: 5546-50.
104. Fahimi-Kashani N, Hormozi-Nezhad MR. Gold nanoparticle-based colorimetric sensor array for discrimination of organophosphate pesticides. Anal Chem 2016; Just accepted manuscript. DOI: 10.1021/acs.analchem.6b01616.
105. Payne JN, Waghwani HK, Connor MG, et al. Novel synthesis of kanamycin conjugated gold nanoparticles with potent antibacterial activity. Front Microbiol 2016; 7: 607.
106. Gholipourmalekabadi M, Sameni M, Hashemi A, Zamani F, Rostami A, Mozafari M. Silver-and fluoride-containing mesoporous bioactive glasses versus commonly used antibiotics: Activity against multidrug-resistant bacterial strains isolated from patients with burns. Burns 2016; 42: 131-40.
107. Giamarellou H, Poulakou G. Multidrug-resistant Gram-negative infections: what are the treatment options? Drugs 2009; 69: 1879-901.
108. Huwaitat R, McCloskey AP, Gilmore BF, Laverty G. Potential strategies for the eradication of multidrug-resistant Gram-negative bacterial infections. Future Microbiol 2016; 11: 955-72.
109. Tillotson GS, Theriault N. New and alternative approaches to tackling antibiotic resistance. F1000prime reports 2013; 5: 51.
110. Seil JT, Webster TJ. Antimicrobial applications of nanotechnology: methods and literature. Int J Nanomedicine 2012; 7: 2767-81.
111. Gholipourmalekabadi M, Nezafati N, Hajibaki L, et al. Detection and qualification of optimum antibacterial and cytotoxic activities of silver-doped bioactive glasses. IET Nanobiotechnol 2015; 9: 209-214.
112. Rostami A, Mozafari M, Gholipourmalekabadi M, et al. Optimization of fluoride-containing bioactive glasses as a novel scolicidal agent adjunct to hydatid surgery. Acta Trop 2015; 148: 105-14.
113. Nezafati N, Moztarzadeh F, Hesaraki S, et al. Effect of silver concentration on bioactivity and antibacterial properties of SiO2-CaOP2O5 sol-gel derived bioactive glass. In: ed.^eds., Key Engineering Materials. Trans Tech Publ 2012; pp. 74-9.
114. Hur YE, Park Y. Vancomycin-functionalized gold and silver nanoparticles as an antibacterial nanoplatform against methicillin resistant Staphylococcus aureus. J Nanosci Nanotechol 2016; 16: 6393-9.
115. Hornos Carneiro MF, Barbosa F, Jr. Gold nanoparticles: A critical review of therapeutic applications and toxicological aspects. J Toxicol Environ Health B Crit Rev 2016; 19: 129-48.
116. Zhou Y, Kong Y, Kundu S, Cirillo JD, Liang H. Antibacterial activities of gold and silver nanoparticles against Escherichia coli and bacillus Calmette-Guerin. J Nanobiotechnol 2012; 10: 19.
117. Lima E, Guerra R, Lara V, Guzman A. Gold nanoparticles as efficient antimicrobial agents for Escherichia coli and Salmonella typhi. Chem Cent J 2013; 7: 11.
118. Shamaila S, Zafar N, Riaz S, Sharif R, Nazir J, Naseem S. Gold nanoparticles: an efficient antimicrobial agent against enteric bacterial human pathogen. Nanomaterials 2016; 6: 71.
119. Han G, Martin CT, Rotello VM. Stability of gold nanoparticlebound DNA toward biological, physical, and chemical agents. Chem Biol Drug Des 2006; 67: 78-82.
120. Ghosh PS, Han G, Erdogan B, Rosado O, Krovi SA, Rotello VM. Nanoparticles featuring amino acid-functionalized side chains as DNA receptors. Chem Biol Drug Des 2007; 70: 13-8.
121. Rana S, Bajaj A, Mout R, Rotello VM. Monolayer coated gold nanoparticles for delivery applications. Adv Drug Deliv Rev 2012; 64: 200-16.
122. De Jong WH, Hagens WI, Krystek P, Burger MC, Sips AJ, Geertsma RE. Particle size-dependent organ distribution of gold nanoparticles after intravenous administration. Biomaterials 2008; 29: 1912-9.
123. Schleh C, Semmler-Behnke M, Lipka J, et al. Size and surface charge of gold nanoparticles determine absorption across intestinal barriers and accumulation in secondary target organs after oral administration. Nanotoxicology 2012; 6: 36-46.
124. Venkatesan R, Pichaimani A, Hari K, Balasubramanian PK, Kulandaivel J, Premkumar K. Doxorubicin conjugated gold nanorods: a sustained drug delivery carrier for improved anticancer therapy. J Mater Chem B 2013; 1: 1010-8.
125. Niidome T, Ohga A, Akiyama Y, et al. Controlled release of PEG chain from gold nanorods: targeted delivery to tumor. Biorg Med Chem 2010; 18: 4453-8.
126. Niidome T, Yamagata M, Okamoto Y, et al. PEG-modified gold nanorods with a stealth character for in vivo applications. J Control Release 2006; 114: 343-7.
127. Yavuz MS, Cheng Y, Chen J, et al. Gold nanocages covered by smart polymers for controlled release with near-infrared light. Nature Mater 2009; 8: 935-9.
128. Yuan H, Fales AM, Vo-Dinh T. TAT peptide-functionalized gold nanostars: enhanced intracellular delivery and efficient NIR photothermal therapy using ultralow irradiance. J Am Chem Soc 2012; 134: 11358-61.
129. Barbosa S, Agrawal A, Rodríguez-Lorenzo L, et al. Tuning size and sensing properties in colloidal gold nanostars. Langmuir 2010; 26: 14943-50.
130. Han Y, Yang X, Liu Y, et al. Supramolecular controlled cargo release via near infrared tunable cucurbit [7] uril-Gold Nanostars. Sci Rep 2016; 6: 22239.
131. Li N, Chen Y, Zhang YM, et al. Polysaccharide-gold nanocluster supramolecular conjugates as a versatile platform for the targeted delivery of anticancer drugs. Sci Rep 2014; 4: 4164.
132. Chen T, Xu S, Zhao T, et al. Gold nanocluster-conjugated amphiphilic block copolymer for tumor-targeted drug delivery. ACS Appl Mater Interfaces 2012; 4: 5766-74.
133. Krishnan G, Edwards J, Chen Y, Benson HA. Enhanced skin permeation of naltrexone by pulsed electromagnetic fields in human skin in vitro. J Pharm Sci 2010; 99: 2724-31.
134. Huang Y, Yu F, Park YS, et al. Co-administration of protein drugs with gold nanoparticles to enable percutaneous delivery. Biomaterials 2010; 31: 9086-91.
135. Larese Filon F, Crosera M, Adami G, Bovenzi M, Rossi F, Maina G. Human skin penetration of gold nanoparticles through intact and damaged skin. Nanotoxicology 2011; 5: 493-501.
136. Seydoux E, Rodriguez-Lorenzo L, Blom RA, et al. Pulmonary delivery of cationic gold nanoparticles boost antigen-specific CD4+ T Cell Proliferation. Nanomed Nanotechnol Biol Med 2016; 12: 1815-26.
137. Bessar H, Venditti I, Benassi L, et al. Functionalized gold nanoparticles for topical delivery of methotrexate for the possible treatment of psoriasis. Colloids Surf Biointerfaces 2016; 141: 141-7.